부산대학교 도서관

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (NAC-CCRT) is an alternative strategy for decreasing tumor size and controlling micrometastases before main treatment. The aim of this study was to investigate This retrospective study included consecutive histologically confirmed Locally Advanced Nasopharyngeal cancer patient treated with NAC-CCRT at the Institute of Oncology RABAT Hospital during the January 2018 to December 2021. CCRT protocols consisted of 3-week cycles of cisplatin 100 mg/m2 with concurrent radiotherapy. NAC consisted of 3-week cycles of cisplatin on day 1 and, 5 fluorouracil on days 1–4, or Doxorubicine on day 1 for a maximum three cycles. Of the 257 patients that received treatment during the study period, 86% patient received NAC-CCRT, and 14 % patient received CCRT (p < 0.001). Median follow-up was 36 months. Significantly more patients with advanced clinical stage (stage IVA-IVB). Toxicities were reported at 42% of the patients, with a higher incidence of neutropenia, anemia, nausea and vomiting, renal toxicity and radiomucositis Grade 3 and 4. At a Median follow-up of 48 months, locoregional control was found in 75% of patients treated, with 11 % of recurrence and 4% metastatic progression. 6% of patients died of their cancer and 4% were lost to follow-up In patients that received neo adjuvant chemotherapy, locoregional relapse should be of concern. High-risk distant metastasis patients (N3 stage) that could achieve survival advantage from NAC-CCRT is an interesting and important topic for further study. [ABSTRACT FROM AUTHOR]